Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for SVRA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2001. Start Trial.
Date Value
June 30, 2026 143.66M
March 31, 2026 176.04M
December 31, 2025 203.13M
September 30, 2025 94.39M
June 30, 2025 120.48M
March 31, 2025 147.85M
December 31, 2024 171.45M
September 30, 2024 199.35M
June 30, 2024 101.73M
March 31, 2024 121.86M
December 31, 2023 140.37M
September 30, 2023 146.54M
June 30, 2023 87.72M
March 31, 2023 98.26M
December 31, 2022 107.78M
September 30, 2022 116.51M
June 30, 2022 127.04M
March 31, 2022 136.48M
December 31, 2021 144.50M
September 30, 2021 155.23M
June 30, 2021 165.38M
March 31, 2021 175.12M
December 31, 2020 64.38M
September 30, 2020 76.63M
June 30, 2020 83.80M
Date Value
March 31, 2020 87.32M
December 31, 2019 101.70M
September 30, 2019 106.80M
June 30, 2019 112.80M
March 31, 2019 101.80M
December 31, 2018 108.22M
September 30, 2018 117.85M
June 30, 2018 82.71M
March 31, 2018 93.70M
December 31, 2017 119.31M
September 30, 2017 74.64M
June 30, 2017 79.77M
March 31, 2017 4.35M
December 31, 2016 7.986M
September 30, 2016 13.19M
June 30, 2016 16.43M
March 31, 2016 20.68M
December 31, 2015 23.89M
September 30, 2015 33.54M
June 30, 2015 42.54M
March 31, 2015 50.11M
December 31, 2014 58.66M
September 30, 2014 45.25M
June 30, 2014 50.22M
March 31, 2014 52.79M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Gilead Sciences, Inc. 11.83B
Insmed, Inc. 757.49M
United Therapeutics Corp. 6.400B
Vertex Pharmaceuticals, Inc. 20.25B
SELLAS Life Sciences Group, Inc. 137.66M

Shareholders Equity (Quarterly) Related Metrics